462 related articles for article (PubMed ID: 24954793)
1. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly.
Bhindi B; Kulkarni GS; Finelli A; Alibhai SM; Hamilton RJ; Toi A; van der Kwast TH; Evans A; Hersey K; Jewett MA; Zlotta AR; Trachtenberg J; Fleshner NE
Eur Urol; 2014 Nov; 66(5):841-8. PubMed ID: 24954793
[TBL] [Abstract][Full Text] [Related]
2. A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression.
Wong LM; Alibhai SM; Trottier G; Timilshina N; Van der Kwast T; Zlotta A; Lawrentschuk N; Kulkarni G; Hamilton R; Ferrara S; Margel D; Trachtenberg J; Jewett MA; Toi A; Evans A; Fleshner NE; Finelli A
Eur Urol; 2014 Sep; 66(3):406-13. PubMed ID: 23664820
[TBL] [Abstract][Full Text] [Related]
3. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
[TBL] [Abstract][Full Text] [Related]
4. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
[TBL] [Abstract][Full Text] [Related]
5. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
[TBL] [Abstract][Full Text] [Related]
6. Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer.
Finelli A; Trottier G; Lawrentschuk N; Sowerby R; Zlotta AR; Radomski L; Timilshina N; Evans A; van der Kwast TH; Toi A; Jewett MA; Trachtenberg J; Fleshner NE
Eur Urol; 2011 Apr; 59(4):509-14. PubMed ID: 21211899
[TBL] [Abstract][Full Text] [Related]
7. The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance.
Ploussard G; de la Taille A; Bayoud Y; Durand X; Terry S; Xylinas E; Allory Y; Vacherot F; Abbou CC; Salomon L
Eur Urol; 2012 Feb; 61(2):356-62. PubMed ID: 21803484
[TBL] [Abstract][Full Text] [Related]
8. Statin use and time to progression in men on active surveillance for prostate cancer.
Jayalath VH; Nayan M; Finelli A; Komisarenki M; Timilshina N; Kulkarni GS; Fleshner NE; Bhindi B; Evans A; Zlotta AR; Hamilton RJ
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):509-515. PubMed ID: 29875433
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
10. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.
Kearns JT; Faino AV; Newcomb LF; Brooks JD; Carroll PR; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y; Lin DW
Eur Urol; 2018 May; 73(5):706-712. PubMed ID: 29433973
[TBL] [Abstract][Full Text] [Related]
11. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.
Godtman RA; Holmberg E; Khatami A; Stranne J; Hugosson J
Eur Urol; 2013 Jan; 63(1):101-7. PubMed ID: 22980443
[TBL] [Abstract][Full Text] [Related]
12. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
[TBL] [Abstract][Full Text] [Related]
13. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.
Iremashvili V; Pelaez L; Manoharan M; Jorda M; Rosenberg DL; Soloway MS
Eur Urol; 2012 Sep; 62(3):462-8. PubMed ID: 22445138
[TBL] [Abstract][Full Text] [Related]
14. Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes.
Hussein AA; Welty CJ; Ameli N; Cowan JE; Leapman M; Porten SP; Shinohara K; Carroll PR
J Urol; 2015 Jul; 194(1):85-90. PubMed ID: 25623742
[TBL] [Abstract][Full Text] [Related]
15. Definitive pathology at radical prostatectomy is commonly favorable in men following initial active surveillance.
Hong SK; Sternberg IA; Keren Paz GE; Kim PH; Touijer KA; Scardino PT; Eastham JA
Eur Urol; 2014 Aug; 66(2):214-9. PubMed ID: 23954083
[TBL] [Abstract][Full Text] [Related]
16. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.
Godtman RA; Holmberg E; Khatami A; Pihl CG; Stranne J; Hugosson J
Eur Urol; 2016 Nov; 70(5):760-766. PubMed ID: 27090975
[TBL] [Abstract][Full Text] [Related]
17. A multi-institutional evaluation of active surveillance for low risk prostate cancer.
Eggener SE; Mueller A; Berglund RK; Ayyathurai R; Soloway C; Soloway MS; Abouassaly R; Klein EA; Jones SJ; Zappavigna C; Goldenberg L; Scardino PT; Eastham JA; Guillonneau B
J Urol; 2013 Jan; 189(1 Suppl):S19-25; discussion S25. PubMed ID: 23234624
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Significance of a Negative Confirmatory Biopsy on Reclassification Among Men on Active Surveillance.
Ganesan V; Dai C; Nyame YA; Greene DJ; Almassi N; Hettel D; Zabell J; Arora H; Haywood S; Crane A; Reichard C; Zampini A; Elshafei A; Stein RJ; Fareed K; Jones JS; Gong M; Stephenson AJ; Klein EA; Berglund RK
Urology; 2017 Sep; 107():184-189. PubMed ID: 28625591
[TBL] [Abstract][Full Text] [Related]
19. Baseline Perineural Invasion is Associated with Shorter Time to Progression in Men with Prostate Cancer Undergoing Active Surveillance: Results from the REDEEM Study.
Moreira DM; Fleshner NE; Freedland SJ
J Urol; 2015 Nov; 194(5):1258-63. PubMed ID: 25988518
[TBL] [Abstract][Full Text] [Related]
20. PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance.
Lokman U; Erickson AM; Vasarainen H; Rannikko AS; Mirtti T
Eur Urol Focus; 2018 Dec; 4(6):867-873. PubMed ID: 28753869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]